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Introduction
Bladder cancer is the ninth most common cancer worldwide based on incidence (Ferlay et al., 2013) . About 75-85 % of patients have non-muscle invasive bladder cancer (NMIBC) at first diagnosis (Babjuk et al., 2011) . Although these tumors are associated with good prognosis, there is a 50 to 70% recurrence rate with a probability of progression to muscle invasiveness in 10 to 30% (Clark et al., 2013; Hall et al., 2007; Sylvester et al., 2006) . Consequently, lifelong surveillance is essential for early recurrence detection.
Both diagnosis and surveillance of bladder cancer rely on cystoscopy and urine cytology methods (Babjuk et al., 2011) . Cystoscopy is highly sensitive and while considered the 'gold standard', it has a significant false-negative rate due to operator-dependent variability or to the difficulty of detecting in situ lesions. Furthermore, it is a costly and invasive procedure which is unpleasant for patients, and carries an additional 10% risk of developing urinary tract infection (Budman et al., 2008; Shariat et al., 2008) . Urine cytology has a higher specificity, ranging from 85 to 100%, but lacks sensitivity (13-75%), especially when it comes to the detection of low-grade tumors (van Rhijn et al., 2005) .
In this context and taking into account the limitations mentioned above, alternative non-invasive methods such as measurements of urinary markers appear more and more appropriate for the diagnosis and surveillance of bladder cancer.
Urine-based biomarker discovery was enabled by the advent of high-throughput
Omics technologies (Ramachandran et al., 2008; Urquidi et al., 2012) . Many markers were identified for their potential utility in the detection and monitoring of bladder cancer such as NMP22, BTA, BLCA-4, CYFRA21-1, survivin, hyaluronic acid and hyaluronidase (Konety et al., 2000; Shariat et al., 2009 Shariat et al., , 2008 Van Tilborg et al., 2009; Vrooman and Witjes, 2008) . Urinary tests have been developed for some of them, including bladder tumor antigen (BTA) and nuclear matrix protein 22 (NMP22).
Two BTA assays, BTA TRAK® and BTA stat® (Polymedco, USA) are approved by the FDA for monitoring of bladder cancer in conjunction with cystoscopy. The Alere NMP22® BladderChek® Test is FDA-approved for the diagnosis and monitoring of bladder cancer patients in conjunction with standard diagnostic procedures.
Compared to urine cytology which has a median sensitivity of 35% and a median specificity of 94% (van Rhijn et al., 2005) , these tests exhibit better sensitivity (24-89% for BTA TRAK®, 57-79% for BTA stat® and 49.5-65% for NMP22) but lower specificity (52-93% for BTA TRAK®, 48-95% for BTA stat® and 40-87.3 % for NMP22) as they are influenced by benign urological conditions such as inflammation, urinary lithiasis or benign prostatic hyperplasia. (Vrooman and Witjes, 2008 ).
The ideal marker should have both high sensitivity and high specificity in order to replace or decrease the need for cystoscopy and guide the surveillance scheme.
Lack of specificity as outlined above for BTA and NMP2 is common to all described urinary markers and the best approach to address this specificity problem of individual markers may be to combine several biomarkers in a panel detectable by a multiplex assay.
In this report, the selection and pre-validation of bladder cancer biomarkers are described. Basis for selection of appropriate marker candidates was the construction of a molecular disease model for bladder cancer and the identification of bladder cancer disease relevant molecular processes taking into account background Omics and literature datasets. Marker selection focused on covering relevant molecular disease processes by selecting at least one marker for every detected biological process also considering available biomarker evidence from scientific literature.
The biomarker candidate set was then evaluated in a technical feasibility study using urinary samples from both bladder cancer patients and healthy donors. The evaluation led to a selection of markers with potential clinical utility to be included in a multiplex assay.
Materials and methods

Specimen and data collection
Urine samples were collected from patients with cystoscopic and histological evidence of bladder cancer and controls. The latter were age and sex matched individuals who had no ongoing or previous cancer, were non-smokers, were not on medication, no urinary symptoms or history of prior bladder disorders apart from occasional urinary tract infection. First pass urines were collected according to a standard operating procedure and were spun at 150g for 10 minutes. The supernatant was aliquoted into 1 ml samples and frozen and stored at -80°C. All individuals gave informed consent for sample donation and the collection was approved by local ethical committee (ref 13/LO/0739). For patients with cancer, the histological report was prepared by an uro-pathologist additionally containing information to tumor stage and grade for each patient.
Bladder cancer model and selection of biomarker candidate set
We first created a set of bladder cancer disease genes consisting (i) of molecular The molecular model was constructed for NMIBC using the bladder cancer molecular features set following the procedure as outlined in Heinzel et al. (Heinzel et al., 2014) with the omicsNET protein dependency network as underlying biological network (Fechete et al., 2013) .
Each process unit of the resulting network was evaluated regarding evidence of association to bladder cancer by comparing the distribution of paper counts for each process unit member to a reference distribution of all human genes having at least one disease association as derived from literature mining. Association to bladder cancer was evaluated for each member of the resulting molecular model based on gene2pubmed mappings of scientific articles retrieved with the following PubMed query: Urinary Bladder Neoplasms [majr] .
In addition a list of marker candidates was generated based on a literature search using the following query followed by the extraction of genes via gene2pubmed:
"Urinary Bladder Neoplasms/urine"[majr] AND "Biological Markers" [mh] .
A third number was derived for each molecule in the molecular model on the number of publications reporting the respective molecule as biomarker for bladder cancer in urine using the following PubMed query: "Urinary Bladder Neoplasms/urine" [majr] AND "Biological Markers" [mh] .
Enzyme-linked immunosorbent assays (ELISA) for urinary biomarkers
Commercially available ELISA kits were used to measure urinary levels of the different markers. Appendix C gives the 20 kits sources and references.
The assays were conducted according to the manufacturer's instructions using an EVO75 robotic platform (Tecan, France).
Engrailed-2 (EN2) protein levels were also determined by ELISA (Morgan et al., 2013) . A monoclonal mouse anti-EN2 antibody, APS1, was generated (Antibody Production Services Ltd., UK) using the synthetically produced EN2 C-terminal 100 amino acids (Biosynthesis Inc., USA). APS1 was used to detect EN2 coated on a 96well plate (Immuno Clear Standard Modules, Cat # 434797 Thermo Scientific, USA).
APS1 was then detected using an anti-mouse IgG (γ chain specific) -peroxidase conjugate (Calbiochem, Germany).
For each assay, a calibration curve in assay diluent and a calibration curve in normal human urine (UTAK Laboratories, USA) were prepared. EN2 calibration curves were generated from dilution series of one of the bladder cancer urinary samples. For all the other markers, calibration curves were prepared using protein standards provided in the ELISA kits. Curve fitting was accomplished using four-parameter logistic regression.
Due to the high degree of variability of voided urine (Thomas et al., 2010; Urquidi et al., 2012) , the concentrations of all markers were normalized to urinary creatinine
(measured with ADVIA 1800 Chemistry System, Siemens) and expressed as a ratio to urinary creatinine values.
Data analysis
A receiver operating characteristic (ROC) analysis was performed to assess the performance of individual markers using the PanelomiX software (http://www.panelomix.net/) (Robin et al., 2013) . PanelomiX also allowed ROC analysis of panels by testing various combinations of markers based on the iterative combination of biomarkers and thresholds (ICBT) method.
Results
Bladder cancer model and selection of biomarker candidate set
The bladder cancer disease gene set held 1384 unique protein coding genes with extracted from the Omics datasets on NMIBC. The constructed molecular model of NMIBC held 520 proteins in 30 process units ranging in size from 3 to 162. Five process units were significantly enriched in proteins associated with bladder cancer as compared to the reference set of genes being associated with at least one disease term via gene2pubmed which were considered as relevant for biomarker selection. AUC values in separating cases from controls in the transcriptomics dataset from Sanchez-Carbayo were significantly higher for members of four additional process units which were also considered for biomarker selection.
A schematic representation of the molecular model is given in the Figure 1 . Based on the number of associations to bladder cancer the most promising molecules were selected for relevant molecular process units. This marker set was complemented by four molecules with high evidence in the scientific literature but not being part of the molecular model resulting in a set of 20 marker candidates as given in Table 1 .
Following the identification of this biomarker candidate set, the evaluation of markers was performed in a two-step selection process: a first evaluation for measurability and detectability in urine samples followed by a second evaluation for confirmation of the markers' selectivity for bladder cancer.
First evaluation of candidate biomarkers: measurability and detectability in urine
The biomarker candidate set consisting of 20 markers was evaluated in urine samples of bladder cancer patients and healthy donors.
Measurability in urine was first ascertained as the performance of many ELISAs may be significantly affected by the urinary environment due to changes in pH or urea/creatinine levels. Columns 2 and 3 of Table 2 present the measurability of each marker (standard solution from kit) in kit manufacturer buffer and standardized urine, respectively. Four out of the 20 ELISA tests weren't able to detect their specific target in urine (CD44, AP1M2, CDH1 and ERBB2). On the contrary, MYC was detected in urine but not in manufacturer buffer.
Detectability in urine samples from bladder cancer patients was then evaluated using the kits able to detect standard solution in urine. Out of the 16 remaining tests, 10
were able to detect markers in patient urine (MMP9, EN2, VEGFA, EGFR, IL8, DCN, MYC, UPK3A, PTGS2 and FGFR3).
Second evaluation of candidate biomarkers: markers' selectivity for bladder cancer
The 10 Marker performance was evaluated using ROC analysis with performance values of the individual markers given in ROC analysis was also performed for multiple markers and PanelomiX thresholdbased algorithm was used to test all combinations of biomarkers (excluding UPK3A).
The best performing marker panel achieved an AUC of 0.871 (95% CI: 0.723-1.0) and of 0.81 (95% CI: 0.640-0.981) after cross-validation including the following six markers: MMP9, VEGFA, IL8, PTGS2, FBLN3, and EN2 (Table 4 ).
Excluding FBLN3 from the model resulted in only marginally reduced overall performance but drastically increased specificity at the expense of reduced sensitivity. As specificity is the parameter of major interest in clinical practice the following marker panel was defined as the one to be multiplexed on a chip (Table 5 and Figure 3 ).
Discussion
Patient-specific biomarker profiles could be of predictive and prognostic utility and could contribute to evidence-based bladder cancer patient management. As no single biomarker can achieve the desired accuracy, a multi-marker test would logically be more likely to be successful. In this regard, we have identified a urinary biomarker candidate set and evaluated it in bladder cancer urine samples, leading to the selection of a panel of five markers: IL8, MMP9, VEGFA, PTGS2 and EN2.
This panel showed a better overall performance than the best individual marker (MMP9), achieving an AUC of 0.865 (0.727-1.0) whereas MMP9 reached an AUC of 0.742 (95% CI: 0.560-0.923). Even though the panel sensitivity is slightly reduced compared to MMP9 (80.0% and 86.7, respectively), its specificity, the most relevant parameter in this context, is considerably increased (93.8% vs. 68.8%).
It is also important to note that due to a relatively small sample size (32 patients), confidence intervals are considerably large.
Non-muscle-invasive bladder tumors have a tendency to recur with a risk of progression to muscle-invasive disease, highlighting the importance of monitoring patients to allow for early recurrence or progression detection (21). We analyzed the potential of our five-marker panel for predicting invasiveness. The role of the various markers with regards to invasiveness was thus evaluated based on the bladder cancer model and on a literature search about the mechanistic link to invasiveness.
Each marker measured in the study was searched in the scientific literature in combination with the search term invasiveness or invasive. Resulting publications were manually screened and paragraphs discussing the respective marker in the context of invasiveness were extracted and collected. In addition, links to other markers from the lists in the publications on invasiveness were extracted and consolidated.
A schematic pathway diagram was constructed based on the information extracted from publications (Figure 4) . This diagram emphasizes the roles of MMP9, VEGFA, EGFR, IL8 and PTGS2 in bladder cancer invasiveness. Indeed, it was found that matrix metalloproteinases, including MMP9, promote tumor invasion and alter microenvironment. They may be thus associated with the development of invasive bladder cancer (Kader et al., 2007) . Moreover, the mechanism of MMP9 activation involves EGF/EGFR signaling activities (Pei et al., 2014) as well as IL8 expression (Inoue et al., 2000) . Angiogenic activity is also enhanced by the expression of VEGF and its receptors VEGFR1/VEGFR2, promoting tumor proliferation and invasion (Kopparapu et al., 2013; Nakanishi et al., 2009 ). Additionally, PTGS2 has a role in bladder cancer development and invasion and is associated with angiogenesis as well (Gee et al., 2008; Margulis et al., 2007) .
Four of the markers included in the final panel are thus linked to invasiveness: IL8, MMP9, VEGFA and PTGS2. The remaining marker, EN2, has no reported link to invasiveness so far in the literature. Nevertheless, its inclusion in the final panel is justified by its contribution to overall performance of the marker panel and previous reports on this marker as bladder cancer marker (Morgan et al., 2013) . EGFR on the other hand was not included in the panel as it did not increase overall performance although mechanistically linked to invasiveness.
Conclusions
Marker candidates were selected on the basis of a molecular disease model for bladder cancer. A 5-biomarker panel (IL8, MMP9, VEGFA, PTGS2 and EN2) was then defined from the candidate set by evaluating the measurability and detectability as well as the selectivity for bladder cancer of the candidate markers in urine samples.
Although this preliminary study only investigated the diagnostic aspect of bladder cancer (in terms of detectability), it was followed by an analysis of the selected panel showing its potential for the prediction of invasiveness.
A scoring system, developed by the European Organization for Research and Treatment of Cancer (EORTC), is already available to predict the risks of both recurrence and progression in individual superficial bladder cancer patients (Sylvester et al., 2006) . However, it is based only on clinical and pathological factors such as the number of tumors, tumor size and T category.
Biomarker profiles, such as defined by our selected panel, could have a great impact on clinical management of bladder cancer patients. Indeed, the surveillance scheme as well as the treatment strategy could be modified according to the risk of invasiveness and/or recurrence assessed at the time of diagnosis and based on the urinary biomarker levels of the defined panel.
Finally, it is important to note that the present study includes a small number of samples (32 patients). Thus, there is a need for further clinical validation with a greater sample size. A multiplex assay shall then be now developed to detect this panel in high-throughput to consolidate this first validation study.
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